Technology platform for therapeutic monoclonal antibody and ADC drugs
With the assistance of its comprehensive functions covering cell clone screening, cell bank construction screening, process development, pilot-scale studies and commercial manufacturing, we have developed a series of antibodies and antibody-drug conjugates (ADCs) through this platform, such as the monoclonal antibody drugs TAB008 (marketed) and TAB014 (Phase III clinical trial ongoing).